Targeting key proximal drivers of type 2 inflammation in disease
The DOI matches its Crossref record; 154 of the 156 references it cites were found in a registry or an index.
Abstract
Systemic type 2 inflammation encompassing T helper 2 (TH2)-type responses is emerging as a unifying feature of both classically defined allergic diseases, such as asthma, and a range of other inflammatory diseases. Rather than reducing inflammation with broad-acting immunosuppressants or narrowly targeting downstream products of the TH2 pathway, such as immunoglobulin E (IgE), efforts to target the key proximal type 2 cytokines - interleukin-4 (IL-4), IL-5 and IL-13 - represent a promising strategy to achieve therapeutic benefit across multiple diseases. After several initial disappointing clinical results with therapies targeting IL-4, IL-5 or IL-13 in asthma, applying a personalized approach achieved therapeutic benefit in an asthma subtype exhibiting an 'allergic' phenotype. More recently, efficacy was extended into a broad population of people with asthma. This argues that the Type 2 inflammation is broadly relevant across the severe asthma population if the key upstream drivers are properly blocked. Moreover, the simultaneous inhibition of IL-4 and IL-13 has shown significant clinical activity in diseases that are often co-morbid with asthma - atopic dermatitis and chronic sinusitis with nasal polyps - supporting the hypothesis that targeting a central 'driver pathway' could benefit multiple allergic diseases.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Lebrikizumab does not affect the binding of IL-13 to the IL-13Rα2 receptor chain, the biological role of which remains unclear81.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [81]
Citations
Cites
GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION
PAUWELS, R. A. (1996) · Arerugī/Arerugi · doi:10.15036/arerugi.45.792 · Cited by 9,994
Williams, H. C., Leung, D. Y. M., Thestrup‐Pedersen, K., & David, T. J. (2000) · Cited by 4,599
Asher, M. I., Montefort, S., Björkstén, B., Lai, C. K., Strachan, D. P., Weiland, S. K., & Williams, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69283-0 · Cited by 4,223
Interleukin-13: Central Mediator of Allergic Asthma
Wills-Karp, M., Luyimbazi, J., Xu, X., Schofield, B., Neben, T. Y., Karp, C. L., & Donaldson, D. D. (1998) · Science · doi:10.1126/science.282.5397.2258 · Cited by 2,617
Development and validation of a questionnaire to measure asthma control
Juniper, E. F., O′byrne, P. M., Guyatt, G. H., Ferrie, P. J., & King, D. R. (1999) · European Respiratory Journal · doi:10.1034/j.1399-3003.1999.14d29.x · Cited by 2,473
Fokkens, W. J., Lund, V. J., Mullol, J., Bachert, C., Alobid, I., Baroody, F., Cohen, N., Cervin, A., Douglas, R., Gevaert, P., et al. (2012) · Rhinology journal · doi:10.4193/rhino12.000 · Cited by 2,387
Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma
Ortega, H. G., Liu, M. C., Pavord, I. D., Brusselle, G. G., FitzGerald, J. M., Chetta, A., Humbert, M., Katz, L. E., Keene, O. N., Yancey, S. W., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403290 · Cited by 2,322
Severity Scoring of Atopic Dermatitis: The SCORAD Index
(2009) · Dermatology · doi:10.1159/000247298 · Cited by 2,273
Pavord, I. D., Korn, S., Howarth, P., Bleecker, E. R., Buhl, R., Keene, O. N., Ortega, H., & Chanez, P. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60988-x · Cited by 2,221
Identification of Asthma Phenotypes Using Cluster Analysis in the Severe Asthma Research Program
Moore, W. C., Meyers, D. A., Wenzel, S. E., Teague, W. G., Li, H., Li, X., D'Agostino, R., Castro, M., Curran-Everett, D., Fitzpatrick, A. M., et al. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200906-0896oc · Cited by 2,129
Research works printed but not linked: 5
- Pawankar, R., Canonica, G., Holgate, S. & Lockey, R. WAO White Book on Allergy 2011–2012: Executive Summary (World Allergy Organization, 2011).
- Wenzel, S. E. et al. Inhaled pitrakinra, an IL-4/IL-13 antagonist, reduced exacerbations in patients with eosinophilic asthma. Eur. Respir. J. 36 (Suppl. 54), 713s (2010).
- Wenzel, S. et al. Dupilumab improves lung function and reduces severe exacerbations in uncontrolled asthmatics with baseline eosinophil levels above and below 300 cells/μl. Am. J. Respir. Crit. Care Med. 191, A3632 (2015).
- Kaiser, J. Medical Officer's Efficacy Review, Genentech, Omalizumab BLA STN 103976/0. US Food and Drug Administration [online] , (2003).
- Groves, R., Wilbrahams, D., Fuller, R. & Longphre, M. Inhibition of IL-4 and IL-13 with an IL-4 mutein (Aeroderm) protects against flares in atopic eczema. J. Invest. Dermatol. 127 (Suppl. 1s), S54 (2007).
Cited by
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110
Self-citationLangan, S. M., Irvine, A. D., & Weidinger, S. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31286-1 · Cited by 1,852
Weidinger, S., Beck, L. A., Bieber, T., Kabashima, K., & Irvine, A. D. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0001-z · Cited by 1,549
Blauvelt, A., de Bruin-Weller, M., Gooderham, M., Cather, J. C., Weisman, J., Pariser, D., Simpson, E. L., Papp, K. A., Hong, H. C.-H., Rubel, D., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31191-1 · Cited by 1,261
Self-citationWenzel, S., Castro, M., Corren, J., Maspero, J., Wang, L., Zhang, B., Pirozzi, G., Sutherland, E. R., Evans, R. R., Joish, V. N., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30307-5 · Cited by 985
Self-citationInterleukin-6 Family Cytokines
Rose-John, S. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028415 · Cited by 799
Atopic dermatitis: an expanding therapeutic pipeline for a complex disease
Bieber, T. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00266-6 · Cited by 623
Type 2 immunity in the skin and lungs
Akdis, C. A., Arkwright, P. D., Brüggen, M.-C., Busse, W., Gadina, M., Guttman‐Yassky, E., Kabashima, K., Mitamura, Y., Vian, L., Wu, J., et al. (2020) · Allergy · doi:10.1111/all.14318 · Cited by 560
Le Floc’h, A., Allinne, J., Nagashima, K., Scott, G., Birchard, D., Asrat, S., Bai, Y., Lim, W. K., Martin, J., Huang, T., et al. (2020) · Allergy · doi:10.1111/all.14151 · Cited by 545
Self-citationCommonality of the IL-4/IL-13 pathway in atopic diseases
Gandhi, N. A., Pirozzi, G., & Graham, N. M. H. (2017) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2017.1298443 · Cited by 493
Self-citationde Bruin-Weller, M., Thaçi, D., Smith, C. H., Reich, K., Cork, M. J., Radin, A., Zhang, Q., Akinlade, B., Gadkari, A., Eckert, L., et al. (2018) · British Journal of Dermatology · doi:10.1111/bjd.16156 · Cited by 479
Self-citationType 2 immunity in allergic diseases
Ogulur, I., Mitamura, Y., Yazici, D., Pat, Y., Ardicli, S., Li, M., D’Avino, P., Beha, C., Babayev, H., Zhao, B., et al. (2025) · Cellular & Molecular Immunology · doi:10.1038/s41423-025-01261-2 · Cited by 362
Paller, A. S., Siegfried, E. C., Thaçi, D., Wollenberg, A., Cork, M. J., Arkwright, P. D., Gooderham, M., Beck, L. A., Boguniewicz, M., Sher, L., et al. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.06.054 · Cited by 399
Self-citationInterleukin‐13: Targeting an underestimated cytokine in atopic dermatitis
Bieber, T. (2020) · Allergy · doi:10.1111/all.13954 · Cited by 382
Type 2 inflammation in asthma and other airway diseases
Maspero, J., Adir, Y., Al-Ahmad, M., Celis-Preciado, C. A., Colodenco, F. D., Giavina-Bianchi, P., Lababidi, H., Ledanois, O., Mahoub, B., Perng, D.-W., et al. (2022) · ERJ Open Research · doi:10.1183/23120541.00576-2021 · Cited by 315
JAK–STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review
Huang, I.-H., Chung, W.-H., Wu, P.-C., & Chen, C.-B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1068260 · Cited by 329
Cytokine Tuning of Intestinal Epithelial Function
Andrews, C., McLean, M. H., & Durum, S. K. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01270 · Cited by 319
Halling, A.-S., Loft, N., Silverberg, J. I., Guttman-Yassky, E., & Thyssen, J. P. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.08.051 · Cited by 288
Paller, A. S., Simpson, E. L., Siegfried, E. C., Cork, M. J., Wollenberg, A., Arkwright, P. D., Soong, W., Gonzalez, M. E., Schneider, L. C., Sidbury, R., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01539-2 · Cited by 281
Self-citationEpigenetics and Allergy: from Basic Mechanisms to Clinical Applications
Potaczek, D. P., Harb, H., Michel, S., Alhamwe, B. A., Renz, H., & Tost, J. (2017) · Epigenomics · doi:10.2217/epi-2016-0162 · Cited by 284
Research Progress in Atopic March
Yang, L., Fu, J., & Zhou, Y. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01907 · Cited by 268
A natural experiment on the effect of herpes zoster vaccination on dementia
Eyting, M., Xie, M., Michalik, F., Heß, S., Chung, S., & Geldsetzer, P. (2025) · Nature · doi:10.1038/s41586-025-08800-x · Cited by 238
Type 2 Inflammation Contributes to Skin Barrier Dysfunction in Atopic Dermatitis
Beck, L. A., Cork, M. J., Amagai, M., De Benedetto, A., Kabashima, K., Hamilton, J. D., & Rossi, A. B. (2022) · JID Innovations · doi:10.1016/j.xjidi.2022.100131 · Cited by 245
Deleuran, M., Thaçi, D., Beck, L. A., de Bruin-Weller, M., Blauvelt, A., Forman, S., Bissonnette, R., Reich, K., Soong, W., Hussain, I., et al. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.07.074 · Cited by 255
Self-citationInflammation mechanism and research progress of COPD
Xu, J., Zeng, Q., Li, S., Su, Q., & Fan, H. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1404615 · Cited by 200
Callewaert, C., Nakatsuji, T., Knight, R., Kosciolek, T., Vrbanac, A., Kotol, P., Ardeleanu, M., Hultsch, T., Guttman-Yassky, E., Bissonnette, R., et al. (2020) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2019.05.024 · Cited by 223
Self-citationTreatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream
Kim, B. S., Howell, M. D., Sun, K., Papp, K., Nasir, A., & Kuligowski, M. E. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.08.042 · Cited by 226
Fang, Z., Li, L., Zhang, H., Zhao, J., Lu, W., & Chen, W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.720393 · Cited by 200
Busse, W. W., Maspero, J. F., Rabe, K. F., Papi, A., Wenzel, S. E., Ford, L. B., Pavord, I. D., Zhang, B., Staudinger, H., Pirozzi, G., et al. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0702-4 · Cited by 189
Self-citationDupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases
Hamilton, J. D., Harel, S., Swanson, B. N., Brian, W., Chen, Z., Rice, M. S., Amin, N., Ardeleanu, M., Radin, A., Shumel, B., et al. (2021) · Clinical & Experimental Allergy · doi:10.1111/cea.13954 · Cited by 192
Self-citationInterleukins 4 and 13 in Asthma: Key Pathophysiologic Cytokines and Druggable Molecular Targets
Pelaia, C., Heffler, E., Crimi, C., Maglio, A., Vatrella, A., Pelaia, G., & Canonica, G. W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.851940 · Cited by 172
Thaçi, D., L. Simpson, E., Deleuran, M., Kataoka, Y., Chen, Z., Gadkari, A., Eckert, L., Akinlade, B., Graham, N. M. H., Pirozzi, G., et al. (2019) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2019.02.002 · Cited by 188
Self-citationJonstam, K., Swanson, B. N., Mannent, L. P., Cardell, L., Tian, N., Wang, Y., Zhang, D., Fan, C., Holtappels, G., Hamilton, J. D., et al. (2019) · Allergy · doi:10.1111/all.13685 · Cited by 181
Self-citationInfections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis
Eichenfield, L. F., Bieber, T., Beck, L. A., Simpson, E. L., Thaçi, D., de Bruin-Weller, M., Deleuran, M., Silverberg, J. I., Ferrandiz, C., Fölster-Holst, R., et al. (2019) · American Journal of Clinical Dermatology · doi:10.1007/s40257-019-00445-7 · Cited by 184
Self-citationPerinatal and Early-Life Nutrition, Epigenetics, and Allergy
Acevedo, N., Alashkar Alhamwe, B., Caraballo, L., Ding, M., Ferrante, A., Garn, H., Garssen, J., Hii, C. S., Irvine, J., Llinás-Caballero, K., et al. (2021) · Nutrients · doi:10.3390/nu13030724 · Cited by 166
Type 2 chronic inflammatory diseases: targets, therapies and unmet needs
Kolkhir, P., Akdiş, C. A., Akdiş, M., Bachert, C., Bieber, T. R. M., Canonica, G. W., Guttman‐Yassky, E., Metz, M., Mullol, J., Palomares, Ó., et al. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00750-1 · Cited by 194
Busse, W. W., Kraft, M., Rabe, K. F., Deniz, Y., Rowe, P. J., Ruddy, M., & Castro, M. (2021) · European Respiratory Journal · doi:10.1183/13993003.03393-2020 · Cited by 164
Bakker, D. S., Ariëns, L. F. M., van Luijk, C., van der Schaft, J., Thijs, J. L., Schuttelaar, M. L. A., van Wijk, F., Knol, E. F., Balak, D., van Dijk, M. R., et al. (2018) · British Journal of Dermatology · doi:10.1111/bjd.17538 · Cited by 161
Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthma
Weinstein, S. F., Katial, R. K., Jayawardena, S., Pirozzi, G., Staudinger, H. W., Eckert, L., Joish, V. N., Amin, N., Maroni, J. M., Rowe, P., et al. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.11.051 · Cited by 155
Self-citationRabe, K. F., Rennard, S. I., Martínez, F. J., Celli, B. R., Singh, D., Papi, A. A., Bafadhel, M., Heble, J., Radwan, A., Soler, X., et al. (2023) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202303-0455ci · Cited by 154
Wollenberg, A., Beck, L. A., Blauvelt, A., Simpson, E. L., Chen, Z., Chen, Q., Shumel, B. S., Khokhar, F. A., Hultsch, T., Rizova, E., et al. (2019) · British Journal of Dermatology · doi:10.1111/bjd.18434 · Cited by 160
Self-citationT-helper cells and their cytokines in pathogenesis and treatment of asthma
Ji, T., & Li, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1149203 · Cited by 154
Blauvelt, A., Simpson, E. L., Tyring, S. K., Purcell, L. A., Shumel, B. S., Petro, C. D., Akinlade, B. K., Gadkari, A. S., Eckert, L., Graham, N. M. H., et al. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.07.048 · Cited by 145
Self-citationDupin, C., Belhadi, D., Guilleminault, L., Gamez, A. S., Berger, P., Frederic de, B. L. A. Y., Bonniaud, P., Leroyer, C., Mahay, G., Girodet, P., et al. (2020) · Clinical & Experimental Allergy · doi:10.1111/cea.13614 · Cited by 143
Blauvelt, A., Guttman‐Yassky, E., Paller, A. S., Simpson, E. L., Cork, M. J., Weisman, J. D., Browning, J., Soong, W., Sun, X., Chen, Z., et al. (2022) · American Journal of Clinical Dermatology · doi:10.1007/s40257-022-00683-2 · Cited by 142
Adverse events of Dupilumab in adults with moderate-to-severe atopic dermatitis: A meta-analysis
Ou, Z., Chen, C., Chen, A., Yao, Y., & Zhou, W. (2017) · International Immunopharmacology · doi:10.1016/j.intimp.2017.11.031 · Cited by 136
Pfaff, C. M., Marquardt, Y., Fietkau, K., Baron, J. M., & Lüscher, B. (2017) · Scientific Reports · doi:10.1038/s41598-017-15892-7 · Cited by 135
Zhu, T. H., Zhu, T. R., Tran, K. A., Sivamani, R. K., & Shi, V. Y. (2018) · British Journal of Dermatology · doi:10.1111/bjd.16734 · Cited by 140
Monoclonal antibodies in type 2 asthma: a systematic review and network meta-analysis
Edris, A., Feyter, S. D., Maes, T., Joos, G., & Lahousse, L. (2019) · Respiratory Research · doi:10.1186/s12931-019-1138-3 · Cited by 135
GZMK-expressing CD8+ T cells promote recurrent airway inflammatory diseases
Lan, F., Li, J., Miao, W., Sun, F., Duan, S., Song, Y., Yao, J., Wang, X., Wang, C., Liu, X., et al. (2025) · Nature · doi:10.1038/s41586-024-08395-9 · Cited by 143
Silverberg, J. I., Yosipovitch, G., Simpson, E. L., Kim, B., Wu, J. J., Eckert, L., Guillemin, I., Chen, Z., Ardeleanu, M., Bansal, A., et al. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.02.060 · Cited by 133
Self-citationBachert, C., Hicks, A., Gane, S. B., Peters, A. T., Gevaert, P., Nash, S., Horowitz, J. E., Sacks, H. J., & Jacob-Nara, J. A. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1356298 · Cited by 139
Fania, L., Moretta, G., Antonelli, F., Scala, E., Abeni, D., Albanesi, C., & Madonna, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052684 · Cited by 128
Cork, M. J., Eckert, L., Simpson, E. L., Armstrong, A. W., Barbarot, S., Puig, L., Girolomoni, G., de Bruin-Weller, M. S., Wollenberg, A., Kataoka, Y., et al. (2019) · Journal of Dermatological Treatment · doi:10.1080/09546634.2019.1612836 · Cited by 122
Anti-Inflammatory Effect of Muscle-Derived Interleukin-6 and Its Involvement in Lipid Metabolism
Nara, H., & Watanabe, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189889 · Cited by 128
Apigenin: A Therapeutic Agent for Treatment of Skin Inflammatory Diseases and Cancer
Yoon, J. H., Kim, M., & Cho, J. Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021498 · Cited by 121
Mashiko, S., Mehta, H., Bissonnette, R., & Sarfati, M. (2017) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2017.07.003 · Cited by 115
Canonica, G. W., Malvezzi, L., Blasi, F., Paggiaro, P., Mantero, M., Senna, G., Heffler, E. M., Bonavia, M., Caiaffa, P., Calabrese, C., et al. (2020) · Respiratory Medicine · doi:10.1016/j.rmed.2020.105947 · Cited by 117
Dupilumab in Inflammatory Skin Diseases: A Systematic Review
Olbrich, H., Sadik, C. D., Ludwig, R. J., Thaçi, D., & Boch, K. (2023) · Biomolecules · doi:10.3390/biom13040634 · Cited by 122
Dupilumab: Mechanism of action, clinical, and translational science
McCann, M. R., Kosloski, M. P., Xu, C. R., Davis, J. D., & Kamal, M. A. (2024) · Clinical and Translational Science · doi:10.1111/cts.13899 · Cited by 120
Pharmacological Regulation of Neuropathic Pain Driven by Inflammatory Macrophages
Kiguchi, N., Kobayashi, D., Saika, F., Matsuzaki, S., & Kishioka, S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112296 · Cited by 112
Indirect Treatment Comparison of Biologics in Chronic Rhinosinusitis with Nasal Polyps
Peters, A. T., Han, J. K., Hellings, P. W., Heffler, E. M., Gevaert, P., Bachert, C., Xu, Y., Chuang, C., Neupane, B., Msihid, J., et al. (2021) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2021.01.031 · Cited by 112
Dupilumab: Basic aspects and applications to allergic diseases
Matsunaga, K., Katoh, N., Fujieda, S., Izuhara, K., & Oishi, K. (2020) · Allergology International · doi:10.1016/j.alit.2020.01.002 · Cited by 109
IL-4/IL-13 axis as therapeutic targets in allergic rhinitis and asthma
Husna, S. M. N., Shukri, N. M., Ashari, N. S. M., & Wong, K. K. (2022) · PeerJ · doi:10.7717/peerj.13444 · Cited by 109
Kim, W.-K., Jang, Y. J., Han, D. H., Jeon, K., Lee, C., Han, H. S., & Ko, G. (2020) · Gut Microbes · doi:10.1080/19490976.2020.1819156 · Cited by 107
Calvani, M., Anania, C., Cuomo, B., D’Auria, E., Decimo, F., Indirli, G. C., Marseglia, G. L., Mastrorilli, V., Sartorio, M. U. A., Santoro, A., et al. (2021) · Nutrients · doi:10.3390/nu13010226 · Cited by 102
JAK/STAT inhibitors for the treatment of atopic dermatitis
Rodrigues, M. A., & Torres, T. (2020) · Journal of Dermatological Treatment · doi:10.1080/09546634.2019.1577549 · Cited by 97
Kim, B., Rothenberg, M. E., Sun, X., Bachert, C., Artis, D., Zaheer, R. S., Deniz, Y. M., Rowe, P., & Cyr, S. L. (2023) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2023.08.017 · Cited by 99
Dupilumab-Associated Adverse Events During Treatment of Allergic Diseases
Kychygina, A., Cassagne, M., Tauber, M., Galiacy, S. D., Paul, C. F., Fournié, P., & Simon, M. (2022) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-022-08934-0 · Cited by 102
da Rosa, J. C., Kim, J., Tian, S., Tomalin, L. E., Krueger, J. G., & Suárez‐Fariñas, M. (2016) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.09.015 · Cited by 96
The mother–offspring dyad: microbial transmission, immune interactions and allergy development
Jenmalm, M. C. (2017) · Journal of Internal Medicine · doi:10.1111/joim.12652 · Cited by 99
Paller, A. S., Siegfried, E. C., Simpson, E. L., Cork, M. J., Lockshin, B., Kosloski, M. P., Kamal, M. A., Davis, J. D., Sun, X., Pirozzi, G., et al. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16928 · Cited by 106
Self-citationHopkins, C. L., Wagenmann, M., Bachert, C., Desrosiers, M. Y., Han, J. K., Hellings, P. W., Lee, S. E., Msihid, J., Radwan, A., Rowe, P., et al. (2021) · International Forum of Allergy & Rhinology · doi:10.1002/alr.22780 · Cited by 99
Current and Emerging Strategies to Inhibit Type 2 Inflammation in Atopic Dermatitis
Haddad, E., Cyr, S. L., Arima, K., McDonald, R. A., Levit, N. A., & Nestle, F. O. (2022) · Dermatology and Therapy · doi:10.1007/s13555-022-00737-7 · Cited by 102
Tsiogka, A., Kyriazopoulou, M., Kontochristopoulos, G., Nicolaidou, E., Stratigos, A., Rigopoulos, D., & Gregoriou, S. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11154431 · Cited by 100
Clinical predictors of remission and persistence of adult-onset asthma
Westerhof, G. A., Coumou, H., de Nijs, S. B., Weersink, E. J. M., & Bel, E. H. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.03.034 · Cited by 94
Bakker, D. S., van der Wal, M., Heeb, L. E. M., Giovannone, B., Asamoah, M., Delemarre, E. M., Drylewicz, J., Nierkens, S., Boyman, O., de Bruin-Weller, M. S., et al. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2021.01.022 · Cited by 94
Xu, C., Song, Y., Wang, Z., Jiang, J., Piao, Y., Li, L., Jin, S., Li, L., Zhu, L., & Yan, G. (2021) · Immunity Inflammation and Disease · doi:10.1002/iid3.490 · Cited by 93
Dupilumab to Treat Type 2 Inflammatory Diseases in Children and Adolescents
Licari, A., Castagnoli, R., Marseglia, A., Olivero, F., Votto, M., Ciprandi, G., & Marseglia, G. L. (2020) · Pediatric Drugs · doi:10.1007/s40272-020-00387-2 · Cited by 91
Nopsopon, T., Lassiter, G., Chen, M., Alexander, G. C., Keet, C. A., Hong, H., & Akenroye, A. T. (2022) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2022.11.021 · Cited by 90
Dupilumab treatment in moderate-to-severe atopic dermatitis: A systematic review and meta-analysis
Wang, F., Tang, X., Wei, C., Xu, L., Mao, H. Z., & Luo, F. (2018) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2018.01.016 · Cited by 84
Personalized medicine—concepts, technologies, and applications in inflammatory skin diseases
Litman, T. (2019) · Apmis · doi:10.1111/apm.12934 · Cited by 95
Toward precision medicine in COPD: phenotypes, endotypes, biomarkers, and treatable traits
Xie, C. H., Wang, K., Yang, K., Zhong, Y., Gul, A., Luo, W., Yalikun, M., He, J., Chen, W., Xu, W., et al. (2025) · Respiratory Research · doi:10.1186/s12931-025-03356-w · Cited by 84
Recombinant allergens for immunotherapy: state of the art
Zhernov, Y. V., Curin, M., Khaitov, M. R., Karaulov, A. V., & Valenta, R. (2019) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000536 · Cited by 87
Exploring the immunopathology of type 2 inflammatory airway diseases
Albloushi, S., & Al-Ahmad, M. S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1285598 · Cited by 95
Howell, M. D., Fitzsimons, C., & Smith, P. A. (2018) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2018.02.012 · Cited by 82
New and emerging treatments for inflammatory itch
Erickson, S., Heul, A. V., & Kim, B. S. (2021) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2020.05.028 · Cited by 79
Bangert, C., Alkon, N., Chennareddy, S., Arnoldner, T., Levine, J. P., Pilz, M., Medjimorec, M. A., Ruggiero, J. R., Cohenour, E. R., Jonak, C., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46540-0 · Cited by 85
Bachert, C., Hellings, P. W., Mullol, J., Naclerio, R. M., Chao, J., Amin, N., Grabher, A., Swanson, B. N., Hamilton, J. D., Guillonneau, S., et al. (2019) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2019.03.023 · Cited by 77
Self-citationPharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Dupilumab in Healthy Adult Subjects
Li, Z., Radin, A. R., Li, M., Hamilton, J. D., Kajiwara, M., Davis, J. D., Takahashi, Y., Hasegawa, S., Ming, J. E., DiCioccio, A. T., et al. (2020) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.798 · Cited by 80
Dupilumab reduces systemic corticosteroid use and sinonasal surgery rate in CRSwNP.
Desrosiers, M., Mannent, L., Amin, N., Canonica, G., Hellings, P., Gevaert, P., Mullol, J., Lee, S. E., Fujieda, S., Han, J. K., et al. (2021) · Rhinology · doi:10.4193/rhin20.415 · Cited by 68
Self-citationExtracellular Vesicles and Asthma—More Than Just a Co-Existence
Alhamwe, B. A., Potaczek, D. P., Miethe, S., Alhamdan, F., Hintz, L., Magomedov, A., & Garn, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094984 · Cited by 77
Chrysin attenuates atopic dermatitis by suppressing inflammation of keratinocytes
Choi, J. K., Jang, Y. H., Lee, S., Lee, S., Choi, Y., Jin, M., Choi, J. H., Park, J. H., Park, P., Choi, H., et al. (2017) · Food and Chemical Toxicology · doi:10.1016/j.fct.2017.10.025 · Cited by 75
Gong, X., Chen, X., Kuligowski, M. E., Liu, X., Liu, X., Cimino, E., McGee, R. F., & Yeleswaram, S. (2021) · American Journal of Clinical Dermatology · doi:10.1007/s40257-021-00610-x · Cited by 78
Wang, L., Xian, Y., Loo, S. K. F., Ip, S., Yang, W., Chan, W. Y., Lin, Z., & Wu, J. C. Y. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105538 · Cited by 80
Maspero, J. F., Katelaris, C. H., Busse, W. W., Castro, M., Corren, J., Chipps, B. E., Peters, A. T., Pavord, I. D., Ford, L. B., Sher, L., et al. (2019) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2019.07.016 · Cited by 74
Self-citationMolecular pathogenesis of genetic and sporadic aortic aneurysms and dissections
Shen, Y. H., & LeMaire, S. A. (2017) · Current Problems in Surgery · doi:10.1067/j.cpsurg.2017.01.001 · Cited by 82
The Relationship of Asthma Biologics to Remission for Asthma
Menzies-Gow, A. N., Szefler, S. J., & Busse, W. W. (2020) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2020.10.035 · Cited by 72
Riccio, A., Mauri, P., Ferrari, L. D., Rossi, R., Silvestre, D. D., Benazzi, L., Chiappori, A., Negro, R. W. D., Micheletto, C., & Canonica, G. W. (2017) · Clinical and Translational Allergy · doi:10.1186/s13601-017-0143-1 · Cited by 72
Myosin light chains 9 and 12 are functional ligands for CD69 that regulate airway inflammation
Hayashizaki, K., Kimura, M. Y., Tokoyoda, K., Hosokawa, H., Shinoda, K., Hirahara, K., Ichikawa, T., Onodera, A., Hanazawa, A., Iwamura, C., et al. (2016) · Science Immunology · doi:10.1126/sciimmunol.aaf9154 · Cited by 77
Metadata
- Authors
- Gandhi, N. A., Bennett, B. L., Graham, N. M. H., Pirozzi, G., Stahl, N., & Yancopoulos, G. D.
- Affiliations
- Regeneron (United States) (US)
- Sanofi (United States) (US)
- Corresponding author
- Gandhi, Namita A.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2015-10-16
- Volume
- 15
- Issue
- 1
- Pages
- 35-50
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2200308911
- Cited by
- 766
- References
- 156
- Citations by year
- 2026: 70 · 2025: 104 · 2024: 113 · 2023: 77 · 2022: 106 · 2021: 99 · 2020: 63 · 2019: 43 · 2018: 33 · 2017: 38 · 2016: 18
- FWCI
- 3.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Regeneron Pharmaceuticals
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Life Sciences › Immunology and Microbiology › Immunology › IL-33, ST2, and ILC Pathways
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Keywords
- type 2 inflammation, IL-4, IL-5, IL-13, asthma, atopic dermatitis, Th2 cells, allergic diseases, IL-4 receptor alpha inhibition, IL-13 inhibition, IL-5 inhibition, personalized asthma therapy, drug candidates
- MeSH terms
- Antibodies, Monoclonal, T-Lymphocytes, Helper-Inducer, Humans, Inflammation, Interleukin-4, Interleukin-5, Models, Immunological, Interleukin-13, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.